Share on StockTwits

Zogenix (NASDAQ:ZGNX) CFO Ann D. Rhoads unloaded 19,229 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $2.10, for a total transaction of $40,380.90. Following the sale, the chief financial officer now directly owns 469,980 shares in the company, valued at approximately $986,958. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

ZGNX has been the subject of a number of recent research reports. Analysts at William Blair reiterated an “outperform” rating on shares of Zogenix in a research note on Monday, May 12th. They now have a $5.00 price target on the stock, down previously from $6.00. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Zogenix in a research note on Friday, April 25th. They now have a $5.00 price target on the stock.

Shares of Zogenix (NASDAQ:ZGNX) traded up 0.82% on Thursday, hitting $1.835. The stock had a trading volume of 1,482,200 shares. Zogenix has a 52-week low of $1.28 and a 52-week high of $5.19. The stock has a 50-day moving average of $2.35 and a 200-day moving average of $3.31. The company’s market cap is $256.1 million. Zogenix also was the target of a large drop in short interest in May. As of May 15th, there was short interest totalling 18,987,265 shares, a drop of 6.3% from the April 30th total of 20,271,501 shares. Currently, 15.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,534,907 shares, the days-to-cover ratio is currently 12.4 days.

Zogenix (NASDAQ:ZGNX) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.64 earnings per share for the current fiscal year.

Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.